An inhibitor of polyQ aggregation
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

C2-8

Item No. 21177

Technical Information
Formal Name
N-(4-bromophenyl)-3-[[(4-bromophenyl)amino]sulfonyl]-benzamide
CAS Number
300670-16-0
Synonyms
  • Polyglutamine Aggregation Inhibitor III
Molecular Formula
C19H14Br2N2O3S
Formula Weight
Purity
≥98%
A crystalline solid
DMF: 33 mg/mlDMSO: 33 mg/mlDMSO:PBS(pH 7.2) (1:3): 0.25 mg/ml
λmax
230, 274 nm
SMILES
BrC1=CC=C(NC(C2=CC=CC(S(NC3=CC=C(Br)C=C3)(=O)=O)=C2)=O)C=C1
InChi Code
InChI=1S/C19H14Br2N2O3S/c20-14-4-8-16(9-5-14)22-19(24)13-2-1-3-18(12-13)27(25,26)23-17-10-6-15(21)7-11-17/h1-12,23H,(H,22,24)
InChi Key
SJJKUNDBFWUAQB-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Product Description

    C2-8 is an inhibitor of polyglutamine (polyQ) aggregation (IC50s = 25 and 0.05 μM for recombinant HDQ51 and in PC12 cells, respectively).1 It also inhibits polyQ aggregation in organotypic hippocampal slice cultures isolated from R6/2 transgenic mice and reduces neurodegeneration in a dose-dependent manner in a Drosophila model of Huntington's disease. C2-8 (100 and 200 mg/kg) reduces huntingtin aggregate size, reduces neuronal atrophy, and improves motor performance in a rotarod test in the R6/2 transgenic mouse model of Huntington's disease.2

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Zhang, X., Smith, D.L., Meriin, A.B., et alA potent small molecule inhibits polyglutamine aggregation in Huntington’s disease neurons and suppresses neurodegeneration in vivo. Proc. Natl. Acad. Sci. USA 102(3), 892-897 (2005).

    2. Chopra, V., Fox, J.H., Lieberman, G., et alA small-molecule therapeutic lead for Huntington’s disease: Preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. Proc. Natl. Acad. Sci. USA 104(42), 16685-16689 (2007).